DE Burlo Group Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

DE Burlo Group Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 40.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 172,580 shares of the company's stock after buying an additional 49,564 shares during the period. Novo Nordisk A/S makes up approximately 3.3% of DE Burlo Group Inc.'s holdings, making the stock its 12th largest position. DE Burlo Group Inc.'s holdings in Novo Nordisk A/S were worth $24,634,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its position in Novo Nordisk A/S by 38.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company's stock worth $9,781,000 after buying an additional 26,067 shares during the last quarter. Bank of New Hampshire raised its holdings in Novo Nordisk A/S by 1,356.8% during the first quarter. Bank of New Hampshire now owns 13,257 shares of the company's stock worth $1,702,000 after purchasing an additional 12,347 shares in the last quarter. Cim LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at about $23,547,000. Burford Brothers Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $1,045,000. Finally, Mark Asset Management LP acquired a new position in Novo Nordisk A/S during the 4th quarter worth approximately $1,035,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on NVO. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $170.00 to $160.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Wednesday, September 18th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a "buy" rating and a $156.00 price target on the stock. Argus raised their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a "buy" rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, September 16th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Buy" and a consensus target price of $145.17.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $2.66 on Thursday, hitting $124.29. The company's stock had a trading volume of 4,368,312 shares, compared to its average volume of 4,279,366. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average price of $132.30 and a 200-day moving average price of $133.14. Novo Nordisk A/S has a 52-week low of $86.96 and a 52-week high of $148.15. The company has a market capitalization of $557.76 billion, a P/E ratio of 42.86, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S's dividend payout ratio (DPR) is 24.83%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.